不同剂量rhG―CSF预防晚期非小细胞肺癌化疗后白细胞减少临床研究.docVIP

不同剂量rhG―CSF预防晚期非小细胞肺癌化疗后白细胞减少的临床研究 　　[摘要] 目的 探析不同剂量的rhG-CSF（基因重组人粒细胞集落刺激因子）预防晚期非小细胞肺癌化疗后白细胞减少的临床效果。方法 方便选取该院2015年6月―2017年7月期间收治的76例晚期非小?胞肺癌患者，根据患者知情同意将其随机分为实验组和对照组，各为38例，两组均采取TP化疗方法，实验组在化疗后以大剂量rhG-CSF进行治疗，对照组在化疗后以小剂量进行治疗，比较两组治疗后白细胞水平回升时间及不良反应。结果 实验组白细胞低于4.0×109个/L有8例（21.05%），对照组白细胞低于4.0×109个/L有20例（52.63%），比较差异有统计学意义（P0.05）。结论 化疗后以大剂量rhG-CSF预防晚期非小细胞肺癌化疗后白细胞减少的临床效果确切，不增加不良反应，促进白细胞回升，值得临床推广。 　　[关键词] 不同剂量；rhG-CSF；晚期非小细胞肺癌；白细胞减少；临床效果 　　[中图分类号] R4 [文献标识码] A [文章编号] 1674-0742（2017）11（b）-0103-03 　　[Abstract] Objective This paper tries to investigate the clinical effect of different doses of rhG-CSF （recombinant human granulocyte colony-stimulating factor） in preventing leukopenia after chemotherapy in advanced non-small cell lung cancer. Methods 76 patients with advanced non-small cell lung cancer admitted to this hospital from June 2015 to July 2017 wereconvenient selection and randomly divided into the experimental group and the control group， with 38 cases in each group. Each group was treated with TP chemotherapy method， the experimental group was treated with high dose of rhG-CSF after chemotherapy. The control group was treated with low dose after chemotherapy. The time of leukocyte recovery and the adverse reaction were compared between the two groups. Results There were 8 cases（21.05%） of the white blood cells lower than 4.0×109/L in the experimental group and 20 cases （52.63%） in the control group， the difference was significant （P0.05）. Conclusion The high dose of rhG-CSF can improve the clinical effect of leukopenia in advanced non-small cell lung cancer after chemotherapy. It does not increase the adverse reaction but promote leukocyte recovery. It is worthy to be popularized. 　　[Key words] Different doses； rhG-CSF； Advanced non-small cell lung cancer； Leukopenia； Clinical effect 　　恶性肿瘤患者化疗后均存在很多毒副作用，如骨髓移植，白细胞减少，中性粒细胞减少等，毒副作用的出现不仅使正常的化疗治疗受到影响，同时也对化疗药物剂量提高受到一定的影响，从而导致治疗效果降低，也增加了患者的痛苦[1-2]。rhG-CSF（基因重组人粒细胞集落刺激因子）在临床上广泛应用于预防癌症化疗后白细胞减少，效果良好，不过对于药物剂量的选择一直是目前临床研